A Randomized, Double Blind Placebo-Controlled, Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BMS-986166 in Healthy Subjects

Phase 1 Completed 66 enrolled Bristol-Myers Squibb

RandomizedParallel-groupDouble-blindScreening

Summary

The primary purpose of this study is to determine if single doses of BMS-986166 are safe and well tolerated in healthy male subjects and female subjects of non-childbearing potential.

Timeline

Start: 2016-07-28
Primary completion: 2017-11-07
Completion: 2017-11-07

Publications

Singhal S, Girgis IG, Xie J, Dutta S, Shevell DE, Throup J. The safety and pharmacokinetics of a novel, selective S1P1R modulator in healthy participants. Expert Opin Investig Drugs. 2020 Apr;29(4):411-422. doi: 10.1080/13543784.2020.1742322.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	BMS-986166	Small molecule	—	Oral

Indications

No indication recorded.